Leading Market Manufacturers

Amgen Inc. (US), Bristol-Myers Squibb Company (US), Celgene Corporation (US), Eli Lilly and Company (US), F. Hoffmann-La Roche Ltd (Switzerland), Merck & Co., Inc. (US), Novartis AG (Switzerland), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Sanofi (France), Johnson & Johnson Services, Inc. (US) and Hospira, Inc. (US)

Anal Cancer Market Overview

Anal Cancer is cancer of the anus or the surrounding area. Anal cancer can be caused by all of the regular causes of cancer, i.e. smoking, chewing tobacco, radiation poisoning, etc., but can also be caused by the HPV virus. In fact, HPV accounts for more than 90% of all anal cancers, making it a closely associated pathogen. Anal cancer is rarely found in younger demographics, with people above 60 being the prime candidate for the disease. It is estimated to cause more than 8,000 new cases in the U.S. in 2019, accompanied by more than a thousand deaths. The five-year survival rate for anal cancer is 66%, a considerable improvement upon some other types of cancer but worrying nevertheless.

Segmentation:

Global Anal Cancer Market has been segmented on the basis of type into squamous cell carcinoma, adenocarcinoma, perianal skin cancer, melanoma, and others.

On the basis of treatment, the global anal cancer market is segmented into chemotherapy, radio therapy, surgery, and others.

On the basis of end user, the global anal cancer market is segmented into hospitals, clinics, research institutes, and others.

Key Questions Answered in This Report:

• What will the market size and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

 Get Full Report @ https://www.marketresearchfuture.com/reports/anal-cancer-market-1530

Industry/Innovation/Related News:

November 30, 2018 – A research group at the University of Alabama (US), published their findings of the study they carried out for the treatments and vaccinations that can be repurposed for HPVs. Preclinical experiments indicate towards the cancer drugs vorinostat, belinostat and panobinostat that can be repurposed to treat infections caused by human papillomaviruses, or HPV.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.